Neogenomics Inc Stock Price, News & Analysis

NeoGenomics and Ultima Genomics have announced a strategic collaboration to enhance cancer diagnostic capabilities using the UG 100 sequencing platform. NeoGenomics has purchased and will install the UG 100 sequencer at their Cambridge, UK innovation center.

The collaboration leverages Ultima's ppmSeq™ technology, which offers cost-effective and low-error sequencing. Recent improvements through the Solaris portfolio have achieved 5x yield improvements, enabling 30X coverage from just 2 nanograms of DNA - a significant advancement for liquid biopsy applications.

This partnership aims to advance oncology diagnostic solutions, particularly in areas like minimal residual disease (MRD) detection and whole genome sequencing. The UG 100 platform's unique architecture specifically addresses the needs of large-scale, cost-effective applications while maintaining high accuracy for early cancer detection.

NeoGenomics reported strong Q1 2025 results with consolidated revenue increasing 8% to $168 million. The oncology diagnostics provider saw its net loss decrease by 4% to $26 million, while Adjusted EBITDA showed remarkable growth of 102% to reach $7 million.

Key performance metrics include:

• Average revenue per clinical test rose 3% to $459
• Consolidated gross profit increased 12% to $73 million
• Gross profit margin reached 44%
• Cash and marketable securities totaled $358 million

The company revised its full-year 2025 guidance to include $12-14 million additional revenue from the Pathline acquisition. Updated projections show consolidated revenue between $747-759 million, representing 13-15% year-over-year growth. Management expects continued acceleration through portfolio expansion and enhanced customer experience.

NeoGenomics (NASDAQ:NEO) has announced the analytical validation of its PanTracer LBx™ assay, a next-generation sequencing liquid biopsy panel for comprehensive pan-solid tumor profiling. The validation study will be presented at the AACR Annual Meeting 2025 in Chicago, along with five additional research abstracts.

PanTracer LBx is a blood-based test analyzing circulating tumor DNA to identify genomic alterations in advanced-stage solid tumors. The validation study demonstrated high performance in identifying key biomarkers like MSI and TMB across multiple cancer types. The company has launched an Evaluation Assessment Program allowing select physicians early access before full commercial release.

Additional presentations at AACR will cover spatial profiling, tumor biology, and genomic co-occurrence, showcasing NeoGenomics' research in areas such as tumor microenvironment characterization, molecular profiling, and renal cell carcinomas.

NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before U.S. markets open. The company will host a webcast and conference call at 8:30 a.m. ET to discuss the results and recent highlights.

Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For telephone access, participants should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using access code 603651.

NeoGenomics (NASDAQ:NEO) has successfully completed its acquisition of Pathline, , a CLIA/CAP/NYS-certified laboratory located in New Jersey. The strategic acquisition strengthens NeoGenomics' commercial footprint in the Northeast United States, particularly in the Tri-state area.

The merger aims to expand access to NeoGenomics' comprehensive oncology test menu and enhance service capabilities, with a focus on accelerating growth in molecular and hematology-oncology testing. This development will provide patients and physicians in the region with broader access to NeoGenomics' high-quality laboratory services.

NeoGenomics (NASDAQ: NEO), a leading oncology testing services company, has announced that Tony Zook has officially taken over as Chief Executive Officer. Zook, who has been a member of the company's Board of Directors since 2023, brings over 30 years of experience in diagnostics and biopharma.

Board Chair Lynn Tetrault highlighted Zook's strong understanding of healthcare and his capability to lead NeoGenomics' next growth phase. As CEO, Zook will focus on execution and growth, particularly in the community oncology setting, where approximately 80% of cancer patients receive treatment.

His leadership approach will emphasize operational discipline, strategic partnerships, and expanding access to advanced diagnostics supporting precision medicine. Zook succeeds Chris Smith, who will remain in an advisory role to ensure a smooth transition.

NeoGenomics (NASDAQ:NEO) has promoted Warren Stone from Chief Commercial Officer to President & Chief Operating Officer, effective April 1, 2025. Stone, with over 25 years of experience, will oversee lab operations, data solutions division, and enterprise operations while maintaining his commercial responsibilities.

Under Stone's leadership since November 2022, the Clinical division has achieved eight consecutive quarters of double-digit revenue growth. The current Chief Operations Officer, Melody Harris, will depart in May. Beth Eastland, Senior Vice President of Enterprise Sales, will support Stone and manage enterprise sales functions.

This organizational restructuring aligns commercial and operations teams to enhance agility and leverage the company's portfolio. The leadership team aims to accelerate growth and profitability while focusing on patient and provider experience.

NeoGenomics (NASDAQ:NEO) has announced the acquisition of Pathline, , a CLIA/CAP/NYS-certified laboratory in New Jersey. This strategic move strengthens NeoGenomics' presence in the Northeast U.S., a historically under-penetrated but growing market.

Founded in 2009, Pathline generates approximately 98% of its revenue from Northeast customers, offering comprehensive subspecialty pathology services including histopathology, immunohistochemistry, cytology, cytogenetics, flow cytometry, FISH, and molecular pathology.

The acquisition brings valuable New York State approvals and aims to enhance NeoGenomics' service capabilities in molecular and hematology-oncology testing. The integration is expected to generate substantial annual cost reductions and become accretive to AEBITDA starting in 2026.

NeoGenomics (NASDAQ:NEO), a leading oncology testing services company, has announced its participation in three major upcoming investor conferences in March:

- TD Cowen 45th Annual Health Care Conference in Boston, MA, featuring a fireside chat on March 4 at 1:50 p.m. ET

- Leerink Partners Global Healthcare Conference in Miami, FL, with a fireside chat scheduled for March 11 at 3:30 p.m. ET

- Barclays 27th Annual Global Healthcare Conference in Miami, FL, hosting a fireside chat on March 13 at 9:00 a.m. ET

All sessions will be available via live and archived webcasts through the Investor Relations section of NeoGenomics' website at ir.neogenomics.com.